The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.
|Videos|April 30, 2021
The Evolving Diagnostic Criteria for Multiple Sclerosis
Join Ahmed Obeidat, MD, PhD; Hesham Abboud, MD, PhD; and Rana K. Zabad, MD, FAAN, for perspectives on how the diagnostic criteria for multiple sclerosis have evolved over time.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Hesham Abboud, MD, PhD
Assistant Professor of Neurology, Case Western Reserve University School of Medicine; Director, Multiple Sclerosis and Neuroimmunology Program, Staff Neurologist, Parkinson’s and Movement Disorders Center, University Hospitals, Cleveland Medical Center - Rana K. Zabad, MD, FAAN
Professor, Department of Neurological Sciences, Chief, Multiple Sclerosis/Neuroimmunology Section, Program Director, Multiple Sclerosis Fellowship, University of Nebraska Medical Center
Key Learning Objectives
- Virtual patient visits during COVID-19 when diagnosing MS
- Review of the revised 2017 McDonald criteria
- Determining MS mimickers
- The future of diagnosing MS
Resources
Advertisement
Related to this article
Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
2
Advances in Spinal Cord MRI for Multiple Sclerosis: Julien Cohen-Adad, PhD
3
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
4
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
5